<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T03:47:55Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/13983" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/13983</identifier><datestamp>2026-09-24T22:20:21Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Valliant, John F.</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author" lang="en_US">Banevicius, Laura</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Medical Physics</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2014-06-18T17:05:49Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2014-06-18T17:05:49Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="created" lang="en_US">2013-12-29</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued" lang="en_US">2014-04</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">opendissertations/8817</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">9758</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">4946738</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/13983</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/21514</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">&lt;p>The photophysical and biological properties of a series of novel molecules that can be used for dual-purpose molecular imaging (optical and nuclear) and therapy of cancer were evaluated. Specifically isostructural [2+1] Re/Tc complexes, a porphyrin conjugate and an antibody-recruiting small molecule construct capable of targeting prostate specific membrane antigen (PSMA) were assessed.&lt;/p> &lt;p>The isostructural [2+1] metal complexes were synthesized to act as an optical probe when prepared using rhenium and a nuclear probe for SPECT when the core metal is &lt;sup>99m&lt;/sup>Tc. The rhenium analogues were incubated with MCF-7 cells and confocal imaging was used to visualize the uptake of a rhenium bipyridine cyclohexyl nicotinate derivative. Uptake of the &lt;sup>99m&lt;/sup>Tc complexes in MCF-7 cells were also measured and showed approximately 7% uptake for the pyridine methanol derivative and 5% for the cyclohexyl nicotinate derivative at 120 min. These results demonstrated the utility of the [2+1] isostructural compounds to create dual purpose optical/nuclear imaging agents.&lt;/p> &lt;p>As a complementary approach to the [2+1] complexes, a series of targeted porphyrin derivatives were prepared and screened in vitro. A set of PSMA targeted chlorin e6 (Ce6) derivatives which act as isostructural molecular imaging probes and targeted photosensitizers for photodynamic therapy (PDT) were evaluated. Ce6 was linked to a potent glutamate-urea-lysine based inhibitor of prostate specific membrane antigen (PSMA), which is a transmembrane protein overexpressed in malignant prostate cancer. Studies in PSMA positive LNCaP cells showed greater uptake of the agents compared to cells with minimal PSMA expression.&lt;/p> &lt;p>Building on the chlorin PSMA studies, a set of antibody-recruiting small molecules that target prostate cancer, and also act as a SPECT imaging agent (when radiolabeled with &lt;sup>123&lt;/sup>I) or a radiotherapeutic (when labelled with &lt;sup>131&lt;/sup>I) were developed. These small molecules consist of a PSMA-inhibitor on one end and 2,4-dinitrophenyl (DNP) group on the other which recruits anti-DNP antibodies. A plate reader assay was developed using a PSMA-positive cell line and fluorescently labeled anti-DNP to observe binding and recruitment of antibodies through fluorescence. An iodine-containing derivative with a PEG&lt;sub>8&lt;/sub> chain between the PSMA inhibitor and DNP was found to be potent (IC&lt;sub>50&lt;/sub> = 14 nM) and is therefore an attractive candidate for combined radio- and antibody recruiting therapy.&lt;/p></dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Master of Science (MSc)</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">EVALUATION OF NEW PROBES AND APPROACHES FOR CORRELATING OPTICAL AND NUCLEAR IMAGING: APPLICATIONS IN CANCER DETECTION AND TREATMENT</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>